Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Impact of Ph-like Gene Signatures on Clinical Outcomes in Adult B-ALL Patients in Resource-Constrained Settings

Keli Lima, César Alexander Ortiz Rojas, Frederico Lisboa Nogueira, Wellington F. Silva, Rita de Cássia Cavaglieri Medeiros, Luciana Nardinelli, Aline de Medeiros Leal, Elvira D. R. P. Velloso, Israel Bendit, Alvaro J Alencar, Charles G. Mullighan, João Agostinho Machado-Neto, Eduardo M. Rego

Blood (2024) 144 (Supplement 1): 2802.

https://doi.org/10.1182/blood-2024-208763

Published: 2024

Journal Articles

Potency and Efficacy of Pharmacological PIP4K2 Inhibitors in Acute Lymphoblastic Leukemia

Keli Lima, Maria Fernanda Lopes Carvalho, Diego A. Pereira-Martins, Wellington F Silva, Mariane Cristina do Nascimento, Lívia Bassani Lins de Miranda, Rita de Cássia Cavaglieri Medeiros, Luciana Nardinelli, Aline de Medeiros Leal, Elvira Deolinda Rodrigues Pereira Velloso, Israel Bendit, Jan Jacob Schuringa, João Agostinho Machado-Neto, Eduardo Magalhães Rego

Blood (2023) 142 (Supplement 1): 5786.

https://doi.org/10.1182/blood-2023-189786

Published: 2023

Journal Articles

Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings

Wellington F Silva, Fernanda Rodrigues Mendes, Marco Sartori, Maria Isabel A Madeira, Katia B Pagnano, Ana Beatriz F Gloria, Elenaide C. Nunes, Luciana Nardinelli, Rita De Cássia Cavaglieri Medeiros, Israel Bendit, Fabiola Traina, Bruno Kosa Lino Duarte, Lorena Lobo Figueiredo-Pontes, Vanderson Rocha, Elvira Deolinda Rodrigues Pereira Velloso, Eduardo Magalhães Rego

Blood (2023) 142 (Supplement 1): 5839.

https://doi.org/10.1182/blood-2023-187902

Published: 2023

Journal Articles

Treatment-Free Response in Chronic Myeloid Leukemia Using Brazilian Imatinib Copies As First Line - Results from Two Prospective Clinical Trials

Renato Torrescasana Centrone, Fernanda S Seguro, Marcelo Bellesso, Luciana Nardinelli, Israel Bendit, Vanderson Rocha, Adelson Alves

Blood (2022) 140 (Supplement 1): 12200–12201.

https://doi.org/10.1182/blood-2022-158969

Published: 2022

Journal Articles

Rhoa Mutation Is a Potential Biomarker Associated with Adverse Prognosis and High- Tumor Burden in Patients with Nodal Peripheral Lymphomas with T-Helper Follicular Phenotype (nPTCL-Thf): Data from a Brazilian Retrospective Cohort of Nodal PTCL

Luis Alberto de Padua Covas Lage, Guilherme Carneiro Barreto, Hebert Fabricio Culler, Jéssica Billar Cavalcanti, Lucas de Oliveira Alves, Luciana Nardinelli, Israel Bendit, Vanderson Rocha, Juliana Pereira

Blood (2021) 138 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2021-148503

Published: 2021

Journal Articles

Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country

Antonio Adolfo Guerra Soares Brandão, MD, Giancarlo Fatobene, MD, Andre Abdo, MD, Luis Alberto de Padua Covas Lage, MD PhD, Israel Bendit, MD PhD, Luciana Nardinelli, MSc, Sheila Aparecida Coelho de Siqueira, MD PhD, Debora Levy, MSc, PhD, Juliana Pereira, MD PhD, Eduardo M Rego, MDPhD, Vanderson Rocha, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142617

Published: 2020

Journal Articles

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Fernanda S Seguro, MD, Felipe VR Maciel, MD, Guilherme O Lopes, Luciana Nardinelli, M.Sc, Vanderson Rocha, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1651.

https://doi.org/10.1182/blood-2019-125989

Published: 2019

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

Douglas R. A. Silveira, Lynn Quek, MD PhD, Anna Corby, B.Sc., Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Grant Vallance, B.Sc., PhD, Benjamin Brown, B.Sc., PhD, Luciana Nardinelli, M.Sc, Wellington F Silva, MD, Elvira DRP Velloso, MD PhD, Fabiola Traina, MD PhD, Andy Peniket, MD, Paresh Vyas, MD PhD, Eduardo M Rego, MD PhD, Israel Bendit, MD PhD, Vanderson Rocha, MD PhD

Blood (2019) 134 (Supplement_1): 2602.

https://doi.org/10.1182/blood-2019-130726

Published: 2019

Journal Articles

E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

Katia B Pagnano, MD, Eliana C Miranda, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Maryanna N Da Silva, Renato Centrone, MD, Monika Conchon, MD, Jaisson Bortolini, MD, Teresa Cristina Bortolheiro, MD, Valquiria Povoa, Luciana Nardinelli, Carmino Antonio De Souza, MD PhD, Israel Bendit, MD PhD

Blood (2017) 130 (Supplement 1): 1596.

https://doi.org/10.1182/blood.V130.Suppl_1.1596.1596

Published: 2017

Journal Articles

Outcome of Patients with Philadelphia Positive Chronic Myeloid Leukemia Post Imatinib Failure: Prognostic Significance of ABL Mutation and Additional Clonal Abnormality.

Monika Conchon, Patricia B Ferreira, Mafalda MY Novaes, Luciana Nardinelli, Mariana Serpa, Pedro Enrique Dorlhiac-Llacer, Dalton FA Chamone, Cristina A Kumeda, Israel Bendit

Blood (2009) 114 (22): 4673.

https://doi.org/10.1182/blood.V114.22.4673.4673

Published: 2009

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia with T315I BCR-ABL Mutation

Kati a BB Pagnano, MD, PhD, Rosana A Silveira, Luciana Nardinelli, Monika Conchon, MD, PhD, Carmino De Souza, MD, PhD, Pedro ED Llacer, MD, Phd, Irene Lorand-Metze, MD, PhD, Vaneuza Funke, MD, Ricardo Pasquini, MD, PhD, Cintia C Mascarenhas, Maria Aparecida Zanichelli, MD, Phd, Nelma CD Clementino, MD, PhD, Israel Bendit, MD, PhD

Blood (2008) 112 (11): 4262.

https://doi.org/10.1182/blood.V112.11.4262.4262

Published: 2008

Journal Articles

Overexpression of the ABC-Transporters BCRP and MDR1 in CML Patients with Resistance to Imatinib and in Untreated CML Patients.

Israel Bendit, MD, PhD, Monika C. Mello, MD PhD, Pedro E. Dorliac-Llacer, MD PhD, Luciana Nardinelli, BSc, Marina Bendit, BSc, Mafalda N.Y. Novaes, MSc, Joao E.B. Neto, MD, Walter M. Lima, MD, Ricardo R. Giorgi, PhD, Dalton A.F. Chamone, MD PhD

Blood (2006) 108 (11): 4812.

https://doi.org/10.1182/blood.V108.11.4812.4812

Published: 2006

NARROW

Impact of Ph-like Gene Signatures on Clinical Outcomes in Adult B-ALL Patients in Resource-Constrained Settings

Potency and Efficacy of Pharmacological PIP4K2 Inhibitors in Acute Lymphoblastic Leukemia

Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings

Treatment-Free Response in Chronic Myeloid Leukemia Using Brazilian Imatinib Copies As First Line - Results from Two Prospective Clinical Trials

Rhoa Mutation Is a Potential Biomarker Associated with Adverse Prognosis and High- Tumor Burden in Patients with Nodal Peripheral Lymphomas with T-Helper Follicular Phenotype (nPTCL-Thf): Data from a Brazilian Retrospective Cohort of Nodal PTCL

Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

Outcome of Patients with Philadelphia Positive Chronic Myeloid Leukemia Post Imatinib Failure: Prognostic Significance of ABL Mutation and Additional Clonal Abnormality.

Outcome of Patients with Chronic Myeloid Leukemia with T315I BCR-ABL Mutation

Overexpression of the ABC-Transporters BCRP and MDR1 in CML Patients with Resistance to Imatinib and in Untreated CML Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only